AI-Integrated pDNA Vaccines for Personalized COVID-19 Protection

A novel system integrating AI, IoT, blockchain, and pDNA vaccines to provide personalized, adaptive, and secure COVID-19 protection

The original patent disclosed a pDNA vaccine against COVID-19, but it lacked the capability to provide personalized and adaptive protection. The new inventive concept addresses this limitation by combining the pDNA vaccine with AI-powered genomics analysis, IoT-enabled sensors, and blockchain-based patient data management, enabling real-time tracking and adaptation to emerging variants

The system consists of a pDNA vaccine, an AI-powered genomics analysis module that analyzes genomic data to identify personalized vaccine targets, an IoT-enabled sensor network that tracks vaccine efficacy and environmental factors, and a blockchain-based patient data management system that securely stores and shares patient data. The AI-driven protein design module engineers novel S protein variants for enhanced vaccine efficacy. The nanoparticle delivery system ensures targeted and efficient vaccine delivery. The blockchain-based platform enables secure sharing of SARS-CoV-2 genomic data and AI-powered predictive analytics for vaccine development

The new claims introduce the integration of AI, IoT, and blockchain technologies with pDNA vaccines, providing a novel and non-obvious solution for personalized and adaptive COVID-19 protection

Alternative embodiments may include the use of different AI algorithms, IoT sensor configurations, or blockchain platforms. Variations may include the integration of additional technologies, such as CRISPR gene editing or advanced materials, to further enhance vaccine efficacy and security

The inventive concept has significant commercial potential in the vaccine development and personalized medicine industries, with potential applications in pandemic preparedness, public health, and biodefense